Literature DB >> 2031918

Total lymphoid irradiation for treatment of intractable cardiac allograft rejection.

S A Hunt1, S Strober, R T Hoppe, E B Stinson.   

Abstract

The ability of postoperative total lymphoid irradiation to reverse otherwise intractable cardiac allograft rejection was examined in a group of 10 patients in whom conventional rejection therapy (including pulsed steroids and monoclonal or polyclonal anti-T-cell antibody therapy) had failed to provide sustained freedom from rejection. Follow-up periods range from 73 to 1119 days since the start of total lymphoid irradiation. No patient died or sustained serious morbidity because of the irradiation. Three patients have had no further rejection (follow-up periods, 105 to 365 days). Two patients died--one in cardiogenic shock during the course of total lymphoid irradiation, the other with recurrent rejection caused by noncompliance with his medical regimen. Total lymphoid irradiation appears to be a safe and a moderately effective immunosuppressive modality for "salvage" therapy of cardiac allograft rejection unresponsive to conventional therapy.

Entities:  

Mesh:

Year:  1991        PMID: 2031918

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  4 in total

Review 1.  [Immunosuppression after heart and lung transplantation].

Authors:  O Wendler; H J Schäfers
Journal:  Med Klin (Munich)       Date:  1997-12

Review 2.  Path to clinical transplantation tolerance and prevention of graft-versus-host disease.

Authors:  Samuel Strober
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

Review 3.  Heart transplantation: approaching a new century.

Authors:  B Radovancević; O H Frazier
Journal:  Tex Heart Inst J       Date:  1999

4.  Tailored total lymphoid irradiation in heart transplant patients: 10-years experience of one center.

Authors:  Pirus Ghadjar; Daniela Joos; Michele Martinelli; Roger Hullin; Marcel Zwahlen; Kristina Lössl; Thierry Carrel; Daniel M Aebersold; Paul Mohacsi
Journal:  Radiat Oncol       Date:  2010-01-16       Impact factor: 3.481

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.